<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715387</url>
  </required_header>
  <id_info>
    <org_study_id>H17-02969</org_study_id>
    <nct_id>NCT03715387</nct_id>
  </id_info>
  <brief_title>Tacrolimus for Malar Edema</brief_title>
  <official_title>Malar Bags After Lower Lid Blepharoplasty and Facelift: A Randomized Controlled Trial of the Effects of Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elective lower eyelid surgery is a common cosmetic procedure. Facial swelling is a common&#xD;
      complication. Studies suggest that this facial swelling is part of a complex inflammatory&#xD;
      process. Topical tacrolimus has long been used to treat various inflammatory skin disorders.&#xD;
      By combining our knowledge of facial swelling and tacrolimus mechanism of action, we can&#xD;
      hypothesize that it can be used as a treatment to prevent this post-operative swelling. The&#xD;
      purpose of this project is to apply topical tacrolimus to one of the patient's cheeks&#xD;
      following facial surgery and compare the incidence of facial swelling to the opposite side&#xD;
      control cheek.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.0 Purpose:&#xD;
&#xD;
      To perform a randomized controlled trial to determine if topical tacrolimus ointment reduces&#xD;
      incidence or severity of post-operative facial edema and malar bags after elective&#xD;
      blepharoplasty and/or facelift.&#xD;
&#xD;
      2.0 Hypothesis:&#xD;
&#xD;
      Topical tacrolimus will reduce the incidence and severity of post-operative facial edema&#xD;
      presenting as malar bags after blepharoplasty and/or facelift.&#xD;
&#xD;
      3.0 Justification:&#xD;
&#xD;
      Elective blepharoplasty is the fourth most common cosmetic procedures performed in North&#xD;
      America. According to a report published by the American Society of Plastic Surgery, eye lid&#xD;
      surgery accounted for 209,000 out of the 1.7 million cosmetic surgical procedures performed&#xD;
      in 2016. Additionally, the number of eye lid surgeries rose 2% in 2016 compared to 2015 [ref&#xD;
      1].&#xD;
&#xD;
      Recurrent or worsened malar bags is a common complication of lower lid surgery. Studies&#xD;
      suggest that post-operative lymphedema is a possible cause of these malar bags. Recent&#xD;
      research into lymphedema pathophysiology shows that post-operative lymphedema is not simply a&#xD;
      result of direct lymphatic injury, but rather a complex fibroproliferative inflammatory&#xD;
      process.&#xD;
&#xD;
      Topical tacrolimus has long been used to treat various inflammatory skin disorders such as&#xD;
      atopic dermatitis and psoriasis safely and effectively. By combining our knowledge of&#xD;
      lymphedema pathophysiology and tacrolimus mechanism of action, we can hypothesize that it can&#xD;
      be effectively used as a treatment to prevent post-operative malar bags as a result of&#xD;
      lymphedema.&#xD;
&#xD;
      4.0 Objectives:&#xD;
&#xD;
      4.1. To apply topical tacrolimus ointment to a randomized cheek in sequential patients&#xD;
      undergoing lower lid blepharoplasty, facelift or both and compare to the contralateral&#xD;
      control cheek.&#xD;
&#xD;
      4.2. To determine if topical tacrolimus affects the incidence and severity of post-operative&#xD;
      malar edema compared to the self-matched contralateral control cheek.&#xD;
&#xD;
      5.0 Research Design:&#xD;
&#xD;
      This is a double blinded randomized controlled trial involving an initial surgery followed by&#xD;
      random topical drug treatment that is self matched to a contralateral control side. There&#xD;
      will be 3 follow up visits for analysis.&#xD;
&#xD;
      6.0 Statistical Analysis:&#xD;
&#xD;
      6.1 Statistical Considerations&#xD;
&#xD;
      The primary endpoint is post operative malar edema which typically occurs 10-20% of the time&#xD;
      following lower lid blepharoplasty and/or facelift procedures. If we expect to reduce the&#xD;
      occurrence to 1-5% the number of patients required to achieve a significant result (α = 0.05&#xD;
      (2-sided), β = 0.20) is 40-100.&#xD;
&#xD;
      No increase in sample size has been made to account for losses to follow-up. In our practice&#xD;
      over the past 10 years we have found that less than 1% of patients do not return for a&#xD;
      follow-up visit.&#xD;
&#xD;
      6.2 Outcome Measures&#xD;
&#xD;
      A custom four point scale will be used to record the outcomes for each cheek:&#xD;
&#xD;
      I: No post operative edema. II: Mild post operative edema. III: Moderate post operative&#xD;
      edema. IV: Severe post operative edema.&#xD;
&#xD;
      Example photographs will be provided to the blinded rater for each category.&#xD;
&#xD;
      6.3 Data Collection&#xD;
&#xD;
      Outcome measurements will be performed by a single observer who will be blinded to the&#xD;
      contents of the containers and which cheek either was applied to. Data will be collected on&#xD;
      study specific data collection forms.&#xD;
&#xD;
      7.0 Procedure&#xD;
&#xD;
      7.1 Surgical Procedure&#xD;
&#xD;
      The lower lid blepharoplasty and facelift procedures will be performed by Dr. Richard Warren&#xD;
      in the usual fashion based on the patient's presenting problem. Specific differences in&#xD;
      technique such as skin only excision vs fat transposition and ORL (Orbicularis Retaining&#xD;
      Legament) division will be recorded and analyzed separately.&#xD;
&#xD;
      7.2 Tacrolimus Application&#xD;
&#xD;
      Patients will be given two containers labelled with &quot;Right&quot; and &quot;Left&quot; to be applied to their&#xD;
      right and left cheeks respectively. The patients will apply the ointment once daily for 4&#xD;
      weeks post operatively. The contents of the containers will be randomized to either the&#xD;
      treatment tacrolimus ointment or the control ointment which will be matched in colour and&#xD;
      consistency to the tacrolimus ointment. They will be given instructions on applying the&#xD;
      ointments based on FDA recommendations.&#xD;
&#xD;
      7.3 Choice of Tacrolimus Dose&#xD;
&#xD;
      The treatment containers will contain 0.1% tacrolimus ointment (marketed as PROTOPIC) based&#xD;
      on FDA recommendations for adult patients. This dose of the drug is known to be sufficiently&#xD;
      absorbed by inflamed skin reaching peak concentrations of 0.05-0.25ng/ml 3-6 hours after&#xD;
      application. This is significantly lower than the accepted safe level of 5-20ng/ml&#xD;
      established based on transplant research. [ref 16,17]&#xD;
&#xD;
      7.4 Post-operative Treatment&#xD;
&#xD;
      Patients will be followed post operatively in the office at 1 week, 4 weeks, and 6 months.&#xD;
      Degree of post operative malar edema will be assessed by a single blinded observer. This will&#xD;
      be recorded using a four point scale. Any side effects or adverse events will also be&#xD;
      recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will serve as their own self matched controls with one study cheek and one control cheek.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Patients will receive a container for each cheek where the contents will be randomized between the study ointment and the control ointment. Only one investigator will have knowledge of the contents. The care providor, patient, and assessor will all be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Malar edema</measure>
    <time_frame>6 months</time_frame>
    <description>Development of malar edema post operatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Edema Face</condition>
  <arm_group>
    <arm_group_label>Tacrolimus Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus Topical 0.1% Topical Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Topical 0.1% Topical Ointment</intervention_name>
    <description>Topical tacrolimus ointment</description>
    <arm_group_label>Tacrolimus Treatment</arm_group_label>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polysporin Ointment</intervention_name>
    <description>Polysporin ointment</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Polysporin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral lower lid blepharoplasty, facelift, or both.&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  -Patients presenting for revision surgery.&#xD;
&#xD;
          -  Patients with a known allergy to tacrolimus.&#xD;
&#xD;
          -  Patients taking medications that alter tacrolimus metabolism:&#xD;
&#xD;
          -  Anticonvulsants: carbamazepine, phenobarbital, phenytoin&#xD;
&#xD;
          -  Antibiotics: rifampicin, rifabutin&#xD;
&#xD;
          -  Antifungal: clotrimazole, ketoconazole, fluconazole, itraconazole&#xD;
&#xD;
          -  Ca++ channel blockers: diltiazem, nifedipine, nicardipine, verapamil&#xD;
&#xD;
          -  Macrolides: erythromycin, clarithromycin, troleandomycin&#xD;
&#xD;
          -  Miscellaneous: cyclosporin A, danazol, bromocriptine, cimetidine, methylprednisolone,&#xD;
             protease inhibitors&#xD;
&#xD;
          -  Patients with previously diagnosed reduced kidney function.&#xD;
&#xD;
          -  Immunocompromised patients.&#xD;
&#xD;
          -  Patients with a history of cutaneous facial malignancies.&#xD;
&#xD;
          -  Patients with active cutaneous facial infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Warren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stahs Pripotnev, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Warren, MD</last_name>
    <phone>604-876-1774</phone>
    <email>tracy@drwarren.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Stuby</last_name>
    <phone>604-876-1774</phone>
    <email>tracy@drwarren.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver Plastic Surgery Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Warren, MD</last_name>
      <phone>604-876-1774</phone>
    </contact>
    <contact_backup>
      <last_name>Tracy Stuby</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Pessa JE, Garza JR. The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J. 1997 Jan-Feb;17(1):11-7.</citation>
    <PMID>19327681</PMID>
  </reference>
  <reference>
    <citation>Nagi KS, Carlson JA, Wladis EJ. Histologic assessment of dermatochalasis: elastolysis and lymphostasis are fundamental and interrelated findings. Ophthalmology. 2011 Jun;118(6):1205-10. doi: 10.1016/j.ophtha.2010.10.013. Epub 2011 Jan 6.</citation>
    <PMID>21211847</PMID>
  </reference>
  <reference>
    <citation>Nijhawan N, Marriott C, Harvey JT. Lymphatic drainage patterns of the human eyelid: assessed by lymphoscintigraphy. Ophthalmic Plast Reconstr Surg. 2010 Jul-Aug;26(4):281-5. doi: 10.1097/IOP.0b013e3181c32e57.</citation>
    <PMID>20551850</PMID>
  </reference>
  <reference>
    <citation>Kpodzo DS, Nahai F, McCord CD. Malar mounds and festoons: review of current management. Aesthet Surg J. 2014 Feb;34(2):235-48. doi: 10.1177/1090820X13517897. Epub 2014 Jan 15. Review.</citation>
    <PMID>24431347</PMID>
  </reference>
  <reference>
    <citation>Cemal Y, Pusic A, Mehrara BJ. Preventative measures for lymphedema: separating fact from fiction. J Am Coll Surg. 2011 Oct;213(4):543-51. doi: 10.1016/j.jamcollsurg.2011.07.001. Epub 2011 Jul 28. Review.</citation>
    <PMID>21802319</PMID>
  </reference>
  <reference>
    <citation>Ghanta S, Cuzzone DA, Torrisi JS, Albano NJ, Joseph WJ, Savetsky IL, Gardenier JC, Chang D, Zampell JC, Mehrara BJ. Regulation of inflammation and fibrosis by macrophages in lymphedema. Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1065-77. doi: 10.1152/ajpheart.00598.2014. Epub 2015 Feb 27.</citation>
    <PMID>25724493</PMID>
  </reference>
  <reference>
    <citation>Avraham T, Zampell JC, Yan A, Elhadad S, Weitman ES, Rockson SG, Bromberg J, Mehrara BJ. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 2013 Mar;27(3):1114-26. doi: 10.1096/fj.12-222695. Epub 2012 Nov 27.</citation>
    <PMID>23193171</PMID>
  </reference>
  <reference>
    <citation>Clavin NW, Avraham T, Fernandez J, Daluvoy SV, Soares MA, Chaudhry A, Mehrara BJ. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2113-27. doi: 10.1152/ajpheart.00879.2008. Epub 2008 Oct 10.</citation>
    <PMID>18849330</PMID>
  </reference>
  <reference>
    <citation>Zampell JC, Yan A, Elhadad S, Avraham T, Weitman E, Mehrara BJ. CD4(+) cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PLoS One. 2012;7(11):e49940. doi: 10.1371/journal.pone.0049940. Epub 2012 Nov 20. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/158f757f-7d51-40b8-a3a4-550811bf0267.</citation>
    <PMID>23185491</PMID>
  </reference>
  <reference>
    <citation>Zhang B, Wang J, Gao J, Guo Y, Chen X, Wang B, Gao J, Rao Z, Chen Z. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009 May 1;107(1):134-43. doi: 10.1002/jcb.22110.</citation>
    <PMID>19241443</PMID>
  </reference>
  <reference>
    <citation>Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. Skinmed. 2008 Jan-Feb;7(1):27-30. Review.</citation>
    <PMID>18174798</PMID>
  </reference>
  <reference>
    <citation>Gardenier JC, Kataru RP, Hespe GE, Savetsky IL, Torrisi JS, Nores GD, Jowhar DK, Nitti MD, Schofield RC, Carlow DC, Mehrara BJ. Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun. 2017 Feb 10;8:14345. doi: 10.1038/ncomms14345.</citation>
    <PMID>28186091</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Richard Warren</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

